New shot takes on botox for Post-Stroke arm tightness

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subjects (or legal representatives) who voluntarily decided the participation of the study and provide written informed consent * Subjects ≥ 19 years of age, inclusive * Subjects who was diagnosed stroke at least 6 months prior to screening * Subjects with MAS score with the wrist flexor score ≥2 and at least one of the elbow flexor or finger flexor score ≥1 * Subjects with a Disability Assessment Scale (DAS) score ≥2 in at least one functional domain, hygiene, dressing, limb position, or pain, selected as the primary treatment goal * Female subjects who are non-childbearing potential, or childbearing\* subjects who are not pregnant, or breastfeeding, a negative serum pregnancy result during screening, and women and men of childbearing potential who agree to use medically acceptable contraceptive methods\*\* or to be sexual abstinence during the study period Exclusion Criteria: * Any medical condition that may affect neuromuscular function (eg, myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis) * Subjects with dysphagia that, in the judgment of the investigator, may interfere with study participation * Subjects with fixed joint/muscle contracture\* at the planned injection sites * Subjects with severe muscle atrophy at the planned injection sites * Subjects with skin abnormalities such as infection, skin disease, or scar at the planned injection sites * History of acute deterioration in pulmonary function within 3 months prior to screening \[including but not limited to hospitalization due to asthma or COPD exacerbation, or pneumonia\] * History of chemodenervation using phenol or alcohol, or surgery at the planned injection site within 24 weeks prior to screening, or scheduled for treatment or surgical intervention during the study * History of tendon lengthening of the study limb within 24 weeks prior to screening, or scheduled surgical intervention at the planned injection site during the study * Previous treatment with botulinum toxin of any serotype in any area within 24 weeks prior to screening * Subjects with ongoing treatment with intrathecal Baclofen * Subjects who require the administration of concomitant medications or implementation of concomitant therapies during the study period